Profile of Patients’ Visceral Leishmaniasis-HIV co-infection in Kabylia

Achour N*, Bouhamed R2 and Harrat Z3

1University Mouloud Mammeri and Chu Dr Nedir Med, Tizi-Ouzou, Algeria
2University Saad Dahleb, Bilia, Algeria
3Service of Ecopepidemiology Leishmaniasis IP Algérie

Abstract

Visceral Leishmaniasis (VL) disease, endemic to Algeria, is a major public health problem for children from rural areas and suffering from malnutrition, this disease currently tends to decrease. However, we found a constant progression in adults over the last twenty years. Indeed, 64 cases of VL in adults were recorded between 1991 and 2010 in Kabylia (Tizi-Ouzou, Bejaia and Bouira) with 18 cases with VL/HIV co-infections. Co-infected men is predominant with 15 cases, a sex ratio of 5 and an average age 35.57 +/- 2.3 years. Typical clinical signs, namely: fever, splenomegaly and hepatomegaly are observed only in 22.2% of the cases; absence of fever (n=4), splenomegaly (n=2), two (n=2) and presence lymphadenopathy (n=5). We also noted the presence of risk factors such as the advanced age of patients and late diagnosis of visceral leishmaniasis usually associated with the advanced stages of HIV infection (III, IV) in mostly multi-infected patients. We also identified five (5) cases of shingles and four (4) cases of digestive candidacies who were the most opportunistic infections observed in our series. Pancytopenia, observed in 2/3 of the cases has been the most consistent biological sign and contributing to the evocation of the VL as the clinical presentation was atypical. The confirmation, by direct examination of bone marrow smears by identifying amastigotes, is observed in all HIV patients (PVH). Western blot and PCR techniques have allowed better monitoring of patients. In 5 cases, the VL revealed the infection of HIV. The care was difficult because of the numerous observed relapses. The unavailability of Amphotericin B, inherent in different factors, compelled us, in some situations, to use the Glucantime as first-line treatment (n=4). Prophylactic treatment based on Pentamidine (n=2), Glucantime (n=2) and amphotericin B (n=12). The evolution was marked by 5 deaths during the first days of treatment anti-Leishmanial and one after several relapses were observed as well as a resistance perhaps to Glucantime resulting in splenectomy.

Keywords: Visceral leishmaniasis; Co-infection VIH; Adults; Kabylian

Introduction

Leishmaniasis is a group of parasitic diseases constantly expanding and widespread in the world. Almost not controlled because neglected, they particularly affect the poorest populations of the world [1]; the determining factor of the spread is the bite of a sand fly [2]. Global warming and environmental changes also contribute to the expansion of the development of their area [1]. Three active players are essential to maintaining the epidemiological chain and sustainability of this zoonotic disease in endemic areas: the reservoir, the vector and environmental changes [3].

Extremely complex disease characterized in humans by a variety of clinical forms; it is the result of a complex entanglement between the environment, the reservoir hosts, vectors, parasites and a mosaic of genetic and immune factors. Its visceral presentation (VL) is the most serious form because fatal if untreated. Reported mainly in tropical areas, it is also present in temperate regions such as the northern Algeria, one of the most affected countries of Maghreb. It is endemic state, with sub-humid bioclimatic and sub arid [4], with the appearance new outbreaks extending west and arid regions of the south [5].

Algeria is a young country, where the aged under 35 represent 63% of the population estimated at 40,590,000 (2016) with a growth rate of 1.92%. Today, it pursues an expanded monitoring program of vaccination and a strict control of waterborne diseases (MTH). Nevertheless, it remains exposed to emerging diseases including HIV/AIDS as well as zoonoses (leishmaniasis, brucellosis, hydatid cyst and rabies). It is a real public health issue sustained by the involvement of different factors (deterioration of environmental health, increasing number of family farms little or no vaccinated, border movement of illegal and uncontrolled livestock, weakness struggles devices, regression of sanitary measures).

The last two decades, leishmaniasis has become a major public health issue. Traditional households accounted for over 50% of reported cases extend out of Kabylia (large and small) [5,6]. We are witnessing the emergence and geographical redistribution of VL, with appearance of new endemic foci accompanied by an increase in scattered cases in the Dry Areas (Illizi, Tamanrasset, Mila and Tissemsilt) previously unaffected [7]. All this led to epidemiological changes sometimes with the coexistence of two clinical forms (VL and cutaneous zoonotic leishmaniasis) at the same household [4].

The progression of the disease is topical, with an increase in VFL adults [8], the emergence of resistant forms, an urbanization of parasitosis and geographic overlay rural homes of VL and urban areas of co-infections VL/HIV. This risks aggravating the epidemiological situation of tuberculosis and HIV/AIDS [5,9], in the region due to co-infection with an impact in terms of psychological, socioeconomic and economic [10] This requires greater vigilance both from clinicians and citizens. That leads us to carry out this work of epidemiological analysis, clinical, biological and therapeutic cases of VL co-infection / HIV / AIDS in Kabylia which remains scarce and little reported in our country [6].
Materials and Method

With the waning of a comparative study of two-part, the first retrospective from 1994 to 1999 and the second prospective descriptive from 2000 to 2010: 18 cases of coinfection HIV/AIDS/VL in adults are diagnosed, all natives and/or residents “in Kabylia” endemic focus which remains the case provider of VL coexisting with canine enzootic in Algeria.

We included in this study all adult patients with HIV-positive serology (2 different ELISA) confirmed by Western blot with identification: direct examination of bone marrow smears of amastigote leishmaniasis or culture (marrow bone), the biopsy (liver, colon and lymph node) and PCR (methods of microscopy and nucleic acid and species identification by sequencing and molecular --other techniques (detection antibody))

For each patient, information was recorded: sociodemographic characteristics (gender, age, occupation, marital status, place of residence), the clinical profile (HIV type, diagnostic delay of the VL to HIV, discovery circumstances, clinical stage according to the WHO classification, clinical symptoms, opportunistic infections have preceded or followed the initiation of treatment, the immunological profile during the VL, the type of treatment established and the evolution of coinfection VL/HIV).

Objective

Review with epidemiological analysis, immunology, clinical, diagnostic and therapeutic of 18 cases of coinfection VL/HIV in Kabylia.

Results and Discussion

In Algeria, the first case of co-infection VL/AIDS was reported in 1985 in a native patient of Boussaâda with AIDS stage with an extensive skin leishmaniasis [11]. In 1999, 426 AIDS cases were reported in Algeria [12] including 13 cases (3%) of co-infection VL/AIDS. The majority of patients are from Kabylia, emigrants living abroad where Algeria [12] including 13 cases (3%) of co-infection VL/AIDS. The majority of patients are from Kabylia, emigrants living abroad where.

A total of 64 cases of VL of adult patients are listed in Kabylia in 20 years. Including 18 cases of VL co-infection HIV/AIDS all natives from the region. Obvious endemic area of visceral leishmaniasis in children and canine enzootic. Known HIV infection

Origin

11 cases are originally from Tizi-Ouzou, 4 from Bejaia and 3 from Bouira. The number of cases is significant in the second period (2P) with 14 cases against 4 to the first (1P).

Gender and age

The men reached a majority with 15 cases, a sex ratio of 5 and a mean age of 35.57 +/- 2.3 years with an extreme of [18-61 years]. 66.7% (10 men/2 women) belong to the age [6,8,13-30].

For their marital status

We note13 married patients among which three HIV-positive women: two of them had lost their husbands due to undetermined causes including one abroad, and the third was diagnosed with the waning of rehospitalization for recurrent pneumonia with a history of ABRT and the loss of a child. One patient had multiple wives (n=5, 2 of them died).

Occupation

The three women of the 18 cases of coinfection VL/HIV were housewives. Two of them lived in the village with their husbands’ family who emigrated abroad. The men 2/3, are immigrants, we find professions like; trader (n=4), farmers (n=3), workers (n=4, daily, café owner), officials (n=2) and informal sector (n=2). High risk factors are reported; such as heterosexuals (11H/3F), bisexuality (2H), an addictive behavior to drug (6H) and a stay in prison in two patients.

All patients in the study were infected with HIV-1. Monitoring their CD4 counts and their viral load was not constant, often not available; nevertheless, we note its frequent feasibility for the prospective study (2P). In the majority of patients (88%) the diagnosis of viral infection was made at a late stage with CD4+ ≤ rate (200/mm³). 38.9% of our patients have no assay result of CD4 T cells. 61.1% of patients had CD4 assay (the rate was between 6-135). They were in stage C of the CDC classification and 63.64% of patients were in stages 3 and 4 of the WHO classification.

During the management of four cases of VL, an HIV+ was revealed significantly to the 2nd P against one case to the 1st P. We note that 14 cases of VL were grafted on HIV+ whose diagnosis in 2/3 of cases was done in advanced clinical stages (III and IV of the WHO classification) with opportunistic infections. Their profound immunosuppressant had increased the risk of morbidity and mortality (Table 1).

Clinical subjects with co-infections VL/HIV differs little from the table immunocompetent association with VL. In our series; fever and weight loss were noted in 14 patients (77.8%), splenomegaly in 16 (88.9%), while hepatomegaly is found in only 1/4 of cases (28.57%) and lymphadenopathy recorded in smaller proportion; three cases (21.4%). Besides these classic forms, atypical forms, pauci or asymptomatic are noted, often the cause of delayed diagnosis conditioning prognosis with a discovery of co-infection in polyinfected patients (n=3) at late stages HIV infection (III and IV). This often reflects the ignorance of the
association. VL often transplanted on the grounds of immuno-deficiency.
We noticed the absence of fever in four patients, no increase in spleen size in both cases and the absence of fever and no increase in spleen size in two male patients. The latter finding was observed in two patients which delayed the treatment of VL while patients were HIV+ (Table 2).

**Biological characteristics**

We do not find specific hematological characteristics during coinfection VL/HIV; few cases with severe anemia (n=2), a mean hemoglobin of 6.50 ± 1.3 g/dl, lymphopenia (n=15), leukopenia (11.1%), thrombocytopenia (5.5%) and neutropenia (5.5%). There are also three cases of bicytopenia and twelve cases of pancytopenia. Nevertheless we note the difficulties encountered in the allocation of these anomalies in VL, to the direct action of HIV itself or the interference of anti-infective drugs multitudes (polyinfected, opportunistic infections) and cytopeniant drugs (as AZT and cotrimoxazol) (Table 3).

The most observed biological association is clinical; pancytopenie with splenomegaly+fever (4 cases) and hepatosplenomegaly+fever (4 times) and to a lesser extent, an isolated lymphadenopathy or splenomegaly or a simple lymphadenopathy and splenomegaly (Table 4).

**Diagnosis of leishmaniasis in HIV-infected patient**

In the whole cases (18) of the study, the diagnosis of VL was established by the direct demonstration of amastigotes in the blood and bone marrow. In both cases the diagnosis VL was supported by the positive results of PCR (polymerase chain reaction) specific peripheral blood Leishmania (1 case) and bone marrow samples (2 cases) (an undeniable contribution). Eight patients were diagnosed by serological tests (indirect immuno fluorescence n=4and Western blot n=4) (Table 5).

* Opportunistic infections frequency Zona (3), hepatitis C (2), cryptococcosis (2), Pneumocystis pneumonia (2), a tubercular disease (2), and hairy leukoplakia.

**Opportunist infections**

The mean opportunistic infections noted in our patients were cutaneous (10), digestive (12), neurology (2) and pulmonary (4) (Table 6).

* Thirteen of our HIV patients were at an advanced stage of the disease when antiretroviral therapy was initiated. Two have not been treated, they were at an advanced stage of coinfection VL/HIV complicated with poliinfection and died the first days of hospitalization. Glucantime was established first intention in 4 patients and fourteen cases with amphotericin B. The prophylaxis was initiated in all patients (n=16), both with Pentamidine twelve with amphotericin B and too with Glucantime. 3 patients presented relapses among which a patient in treatment failure requiring splenectomy (Table 7).

**The evolution**

The evolution of the disease is marked by the frequency of relapses observed in three patients all supported at the P2 of the study and two of which died.

In a recent study, we noted five deaths: one during the P1 study, three during the P2 and one during the follow-up in April 2016. Two are lost to follow-up and the others are still under surveillance, two of which are no longer receiving maintenance treatment.

**Comments**

The World Health Organization estimates that about 900,000 to 1.3 million new cases of leishmaniasis are reported per year, of these, approximately 0.2-0.4 million are of visceral leishmaniasis (VL) [3].

| Period   | 1991-1999 | 2000-2010 | Total |
|----------|-----------|-----------|-------|
| Signs    |           |           |       |
| Fever    | N%        | N%        | Nb    |
|          | 3 75      | 11 7.66   | 14    |
| Slimming | 4 100     | 11 7.66   | 15    |
| Splenomegaly | 3 75      | 13 9.28   | 16    |
| Hepatomegaly | 1 25      | 5 35.7    | 6     |
| Lymphadenopathy | 2 50      | 3 21.4    | 5     |

**Table 2:** Clinical signs.

| Period   | 1991-1999 | 2000-2010 | Total |
|----------|-----------|-----------|-------|
| Anomaly  | N         | N         |       |
| Anemia ≤ 5 gr/dl | 1         | 1         | 2     |
| Leucopenia | 1         | 2         | 3     |
| Bicytopenia | 0         | 2         | 3     |
| Pancytopenia | 2         | 10        | 12    |

**Table 3:** Biological characteristics.

| Clinical association | 1991-1999 | 2000-2010 | Total |
|----------------------|-----------|-----------|-------|
| Sgg+F+Pcp            | N         | N         | Nb    |
| Sgg+F+Lp             |           |           |       |
| Sgg+F+An             | 1         | 1         | 2     |
| Sgg+F+Adp+Pcp        | 1         | 1         | 2     |
| Sgg+F+Adp+Lp+Pcp     | 1         | 1         | 1     |
| Hpg+Sgg+F+Pcp        | 1         | 3         | 4     |
| Hpg+Adp+Pcp          | 1         | 1         | 1     |
| Hpg+Adp+Lp           | 1         | 1         | 1     |
| Hpg+Adp+Lp           | 1         | 1         | 1     |
| Adp+Sgg+Lp           |           |           |       |
| Adp+Lp               |           |           |       |

* F: Fever; Sgg: Splenomegaly; Hpg: Hépatomegaly; Adp: Adenopaty; An: Anemia; Lp: Leucopenia; Bcp: Biliopenia; Pcp: Pancytopeny

**Table 4:** The most biological/clinical association.

| Period   | 1994-1999 | 2000-2010 | Total |
|----------|-----------|-----------|-------|
| Exams    | Born marrow |           |       |
|          | N %        | N %       |       |
| PCR+     | 11 7.2     | 2         |
| Culture+ | 11 7.2     | 1         |
| Serology | 2/4        | 2/5       | 4/9   |
| WB+      | 2/4        | 2/5       | 4/9   |

**Table 5:** Diagnoses.

| Opportunist | Period   | 1991-1999 | 2000-2010 | Total |
|-------------|----------|-----------|-----------|-------|
|             | N %      | N %       |           |       |
| Hepatitis C | /        | 4 28.6    | 4         |
| Hepatitis B | /        | 1 7.2     | 1         |
| Tuberculosis Pneumonia | 1 25      | 1 7.2 | 1   |
| Zona        | /        | 5 35.9    | 5         |
| Seborrheic dermatitis | 2 25      | 3 21.8 | 3   |
| Meningitis cryptococcosis | /25    | 2 14.3 | 2   |
| Pneumonia pneumocystis | 1 25     | 1 7.2 | 1   |
| Hairy leukoplaika | /        | 2 14.3 | 2   |
| Colonic Lymphoma | /        | 1 7.2 | 1   |
| Digestive candidiasis | 2 50     | 4 28.6 | 2   |

**Table 6:** Opportunist infections.

| Glucantime* | Amphotericin B* | Pentamidine* | Total |
|-------------|-----------------|--------------|-------|
| 1st intention | 4 | 14 | 18 |
| 2nd intention | 2 | 14 | 16 |
| Interview   | 2 | 12 | 16 |

**Table 7:** Therapeutic lines.
Visceral leishmaniasis is the most severe form of a parasitic disease transmitted by insects prevalent in 98 countries [26]. HIV infection is a major public health problem. Globally, 36.9 million people living with HIV with 2.0 million new infections per year [31]. 35 countries currently report cases of co-infection (Leishmania/HIV) in 2-12% of all cases of VL. This proportion increases dramatically [16].

The first case of leishmaniasis associated with HIV has been reported in Algeria in 1985 and in the region of Kabylia in 1991 [14]. Visceral leishmaniasis (VL) and HIV (HIV) co-infection has emerged as a model of severe disease [32]. Between 1991 and 2010, 64VL cases were recorded in three regions of Kabylia (Tizi-Ouzou, Bejaia and Bouira) with 18 cases of coinfection VL/HIV/AIDS. In Algeria very few cases of VL/HIV coinfections are reported (less than 35 cases). The historical entity of infantile VL cases is not current. The endemic Kabyl region is the bigger provider of infantile cases in our country, but faces a constant increase in the adult form and VL/HIV co-infections these two last decades. This work is a comparative study between two periods P1 retrospective study with 8 cases of which 4 co-infections VL/HIV and P2 exploratory study with 56 cases adult of which 14 cases of co-infections.

The presumed parasite infestation place corresponds to areas of endemic diseases known to VL (Tizi-Ouzou, Bejaia and Bouira), which is also the birthplace and/or patient residence. As for literature, it reduces the frequency of occurrence of this association (parasitic diseases-HIV) in case of travel and/or stay in immunocompromised patients of endemic area can be up to 2 or 3 years later [11,28,33,34].

VL is an opportunistic parasitosis emerging since 1980 on the southern shore of Europe [3,20,35], where nearby 1500 cases of HIV/Leishmania co-infection are reported by Alvar [3]. In the last decade in the Maghreb, its incidence in HIV+adults is steadily increasing.

By 2015, 51% of all adults living with HIV (approximately 17.8 million) are women (aged 15 years and older) [25]. In the Maghreb, women account for 38% of newly infected adults, nearly half (48%) of whom are between the ages of 15 to 24. In our study the incidence of HIV infection remains generally higher in men than in women 15 versus 3 [17,36,37].

The sexual contamination remains in our country the most common mode of transmission. Contamination via heterosexual intercourses is 88.9% of cases (18.7% women). Men who have sex with men (MSM) are the only group whose HIV-positive findings increased between 2003 and 2011 [36,38]. However, in Europe, the use of IV drugs is a major risk factor [36], affecting 76% of cases in a study of 781 cases between 1990-1998 and 67% of cases on a study of 95 cases performed between 2001-2006 [5,11].

The role of substance abuse (injectable way) in the transmission of the parasite is reported respectively 92.5% and 50% of cases by Montalban and Cabier [22,39], Desjeux and Alvar in a series of 1911 cases, patients between 31-50 years are reported in 77.3% of cases, for the most part male (85%) with 70% of injecting drug users, for whom serology was falsely negative in 40% of cases [32,40].

This mode is not noted in our series and there is a decline in its incidence since the awareness of populations at risk with the use of sterile single material. In two of our patients with drug addiction (acquired during stays abroad), we find the concept of needle exchange with people unknown serological profile and anarchic sexual behavior. Therefore it was difficult to determine the mode of contamination. For the women of our series who contracted the infection, they were not aware of the disease of their spouses; moreover their status was only discovered during a hospitalization for opportunistic infection (pneumocystosis, dermatosis mucocutaneous and candidiasis) and advanced stages of the disease. This indicates unconsciousness infected patients, who often hide their disease especially for societal considerations (taboo).

In a series of 965 cases studied between 1990 to 1998, the average age of patients was 38.6 years and 38.9 years in another series of 253 cases studied between 2001 to 2006 [11,41]. The average age of our series 35.57 +/- 2.3 years (18-61) is close to the averages quoted and below the average (37 to 48 years) reported by the [WHO].

Many studies suggest that VL will gladly transplant in patients with evidence of immunosuppression with a CD4 count <200/mm^3 (2). In our study, this assay was performed only in 61% of cases (n=11), with an average CD4 of 40/mm^3 with extremes of 6 to 135/mm^3. In a few cases, viral loads were performed (n=4) [39]. All this leads us to screenings when acquired immunosuppression, if stays of recent or old travel or transit through traveler from increased traffic to airports from endemic areas.

In two patients, the diagnosis of co-infection was made at admission, in 10 cases of HIV infection had been known for at least 2 years and one year in one case. In all five cases (27.8%), or VL revealed HIV-seropositive (Montalban 10%) [22], we find the notion of pets (particularly dogs) in the immediate vicinity associated with a permanent residence in endemic areas [15]. 11 patients classified as stage C AIDS CDC classification have proven track record of opportunistic infections before or during the first episode of VL [36].

Clinical manifestations were mostly atypical, suggesting different infections, which resulted in delay in initiating treatment. The weight loss reported in both VL and HIV infection is multifactorial. This weight loss is noted in 83.3% and has often been the reason for consultation in our series. Fever and weight loss were associated with 14 cases in more than 3/4 of the cases (77.8%) and splenomegaly in almost all cases 16% (88.9%), whereas hepatomegaly was only noted in six patients: 1/3 of cases (33.3%), and lymphadenopathy in a lesser proportion: five cases (21.8%). The clinic observed in our patients merges with the literature. Alvar in 2002 noted the presence of fever in all patients as well as splenomegaly and paleness [40]. Other authors state that the clinical features are not always present and that non-specific signs are often confused with those of other opportunistic infections, parasitic, fungal, bacterial or viral (data observed by Cabier, Montalban, Pagliano) [22,28,39].

The absence of major signs: fever (22.2%), splenomegaly (11.1%) or both were particularly observed in the second study period (P2). Inconstancy of these signs is observed in the series but has been little reported [42].

The classic triad splenomegaly, anaemia and fever is little reported in the literature in patients co-infected VL/HIV, as well as in our series 11.2% (n=2) [18].

* Different hematologic events are reported individually to the waning of the VL and/or HIV. When coinfection, abnormal blood counts are almost constant, often compounded by the side effects of multiple therapeutic: ARVs and anti-infective (antibiotics, antifungal and antiparasitic) conditioning an already diminished prognosis co-infection.

Pancytopenia is the most observed biological perturbation, reported in the literature [36] and noted in more than 3/4 of the cases.
The main opportunistic infections observed in our work are: Cutaneous localization (3); Zona (5), mouth candidiasis (2), hairy leukoplakia (2), digestive with hepatitis C (2), neurology; cryptococcal meningitis (2), pneumonia with Pneumocystis pneumonia (1) and tuberculosis (1) [24,27].

*Treatment and follow-up, the care of our patients with established treatments and scalable monitoring was consensual. The strength of the series studied is small (n=18) making it impossible to draw statistical conclusions. During VL/HIV co-infection, the two pathogens target the same cells and exert a synergistic deleterious effect on the cellular immune response, hence the more rapid evolution of the retroviral infection and the difficulties encountered during treatment; Two patients received only a few days of anti-VL (Amphotericin B) treatment before they died, they were at an advanced stage of VL/HIV and poly-infected co-infection.

13 co-infected patients had a classic response to treatment Leishmania (with maintenance) and a conventional monitoring to date; 9 were undergoing ARV therapy to discover VL. 5 had CD4 < 135/mm³ at diagnosis of VL with an HIV viral load more than 50,000 copies/ml (n=2), 11 were under Amphotericin B in 1st intention and maintenance, was vitiated by any side effects related to treatment, only two patients had a change of ART for the treatment of co-infection.

During the long follow-up of our patients, many relapses were managed in 3 patients.

The first case was 23 years old when he was diagnosed with VL, he was originally from Bejaia and had been on antiretroviral therapy since 2007 and he was diagnosed with co-infection at the end of 2008 and was given Glucantime and then Amphotericin B with maintenance of therapy. Immune reconstitution is slow, during follow-up, several relapses are noted. In spite of the splenectomy carried out in 2014, the marrow remains rich in parasites, indicating either the presence of a parasitized zone inaccessible to the treatment or the absence of immune restoration or the resistance of the parasite. Intolerance and adverse effects of treatments (cardiac toxicity, renal and hypocalcemia), unavailability of therapeutic alternative (such as Amphotericin B liposomal not ATU) make the patient therapeutic escape and died in April 2016.

The second patient (n=6 relapses), Glucantime was used as first-line treatment and maintenance but not observing, 2nd line with Amphotericin B then relay maintained at 2 mg/kg per month. Despite the reduction in viral load that decreased to the point of becoming undetectable (more assiduous patient) with a CD4 count > 200/mm³, the patient continued to relapse, switching to maintenance dose of 10 mg/Kg/week with Amphotericin B it was effective.

The third unruptly patient, relapse (n=3), multiple addictive behavior; addict (IV and oral, ethyl), with CD4 counts at diagnosis of VL 09/ mm³ received amphotericin B (first-line and maintenance) and then lost sight of not observing its treatment modification ARV therapy in the treatment of coinfection, died in a clinical picture suggestive of encephalitis meningoencephalitis with polyinfection (meningean cryptococcosis, hepatitis C, digestive candidiasis) after stopping treatment. Davidson reports 80% recidivism in the case of co-infection [44] and Alvar reported an increase in this frequency when using DP as in co-infections [45]. The unavailability of other therapeutic alternatives in Algeria (no ATU), (Ambisome*, Pentamidine*, Itraconazole* Allopurinol*) explains the absence of molecular association in our treatments especially in cases with repeated relapses. This could enhance the effects of drugs, reduce the duration and reduce the risk of resistance development (mentioned in both cases) [46,47].

From these examples we can see that the factors that maintain relapse and determine the prognosis is the fact of living in a high endemic areas, the support of delay, advanced co-infection stadiums, immunosuppression Profoundness during the first episode of VL, the attainment of different organs (high parasitic load), the delay or lack of restoration of immunity and the chronicity of evolution.

Although there is a theoretical consensus in the management of patients co-infected with HIV and visceral leishmaniasis, driving in practice it is not always easy and often put in check. The atypical clinical manifestations wander the diagnosis of visceral leishmaniasis. That often constitutes a circumstance of discovery of HIV infection and often at a late stage of immunosuppression. The frequency of stibio-resistance, drug toxicity molecules (Glucantime*, amphotericin B), the unavailability of lipid amphotericin B drift (excessive cost) and the long duration of treatment (processing) complicate the observation and monitoring of patients and promote relapse.

Factors influencing the choice of our therapeutics that was not so wide that this view, we do not have the ATU for other molecules in the cost of treatment and the duration of hospitalization. The price of amphotericin B lipid formulations is inaccessible in developing countries.

**Conclusion**

This study shows the complexity of the management of HIV/ visceral Leishmaniasis co-infection. The diagnosis is difficult because the clinical forms are atypical. The pathogenic effects of HIV infection and VL are potentiated in patients co-infected with HIV/VL, increasing morbidity/mortality, with less effective first-line therapy. The risks of relapse are linked to ‘sanctuary zones’ inaccessible to the treatments or
resistances of the parasite to the molecules used despite their toxicities in monotherapy in the first line therapeutic due to lack of molecular alternatives (not ATU, excessive cost). Immune restoration by ARVs is essential but insufficient for healing.

In the last decade, the association of visceral leishmaniasis and HIV is often brought to the banks of the Mediterranean. In Algeria, VL is a public health problem and the incidence of co-infection has not been established with precision. Kabylie, endemic area for visceral leishmaniasis, sees a number in co-infection in adults, progress. There is a complex management of HIV/visceral leishmaniasis co-infection. Diagnosis is difficult because clinical forms are atypical. The pathogenic effects of HIV infection and potentiate VL in patients co-infected with HIV/VL, the upper limit morbidity/mortality with a less effective first line of treatment and the risk of relapse, of “refuges” inaccessible treatment. Immune restoration with ARVs is essential but not sufficient for healing.

References

1. Aljar V, Yactayo S, Bern C (2006) Leishmaniasis and poverty. Trends Parasitol 22: 552-557.
2. Duvallet G (2008) Parasiites. vecteurs de pathogènes et changements climatiques. Hydroécol Appl 15: 87-96.
3. Aljar V, Vélez ID, Bern C, Herrero M, Desjeux P, et al. (2012) Leishmaniasis worldwide and global estimates of its incidence. PLoS One 7: e35671.
4. Bach F (2006) Aspects épidémiologiques et cliniques des leishmanioses en Algérie. Lettre de l’infectiologue—Tome XXI-n°1-(janvier-février 2006).
5. Dedet JP, Addadi K, Lannuzel B (1977) Epidemiology of leishmaniasis in Algeria 7 Visceral leishmaniasis in the Grande Kabylie focus. Bull Soc Pathol Exot Filiales 70: 250-265.
6. Harrat Z, Berrouane Y, Ben Abdesslam S, Belkaid M, Tabel-Derraz O (1992) Visceral leishmaniasis in Algeria. Evolution of visceral leishmaniasis in the Grande Kabylie area (1985-1990). Arch Inst Pasteur Alger 58: 255-272.
7. Belazouz S (1985) Épidémiologie des leishmanioses en Algérie: Etude des réservoirs. Analyses chimio taxonomique des parasites. Thèse pour l’obtention du grade de Docteur en sciences médicales.
8. Hakem D, Médacoud S, Boucalima M, Ouadahi N, Amrane A (2007) Leishmanioses viscérales: Particularités cliniques et difficultés thérapeutiques. Congrès SNFMI Béziers-Narbonne.
9. Duree J, Reynes J, Pratlong F, Lampaury I, Rioux JA, et al. (1995) Visceral leishmaniasis in HIV-infected patients in the south of France. Bull World Health Organ 73: 245-246.
10. Thakur CP (2000) Socio-economics of visceral leishmaniasis in Bihar (India). Trans R Soc Trop Med Hyg 94: 156-157.
11. Dedet JP (1999) Les Leishmanioses. Edition Ellipses 253.
12. Alam A, Bouadjiadja S, Cherrouf A, Soufi A (1999) Données épidémiologiques sur l’infection VIH en Algérie. Arch Inst Pasteur Algérie 63: 37-50.
13. Grant AD, Djomand G, Smets P, Kadio A, Coulibaly M, et al. (1997) Profound immunosuppression across the spectrum of opportunistic disease among hospitalized HIV-infected adults in Abidjan, Côte d’Ivoire. AIDS et al 11: 1357-1364.
14. Harrat Z, Belkaid M (2002) Co-infection Leishmaniose Viscérale — Sida en Algérie. Santé — Algérie. n°7 37-38.
15. Herwaldt BL (1999) Leishmaniasis. Lancet 354: 1191-1199.
16. Linderst JA, Cunha MA, Queiroz IT, Moreira CH (2016) Leishmaniasis–HIV coinfection: Current challenges. HIV/AIDS 8: 147-156.
17. Le Vu S, Le Strat Y, Barin F, Pillonel J, Cazein F, et al. (2010) Population-based HIV-1 incidence in France, 2003-2008: A modelling analysis. Lancet Infect Dis 10: 682-687.
18. Lima IP, Muller MC, Holanda TA, Harhay M, Costa CH, et al. (2013) Human immunodeficiency virus/Leishmania infantum in the first foci of urban American visceral leishmaniasis: Clinical presentation from 1994 to 2010. Rev Soc Bras Med Trop 46: 156-160.
19. Lindoso JA, Cola GF, Cruz AM, Goto H, Maia-Elkhoury AN, et al. (2014) Visceral Leishmaniasis and HIV Coinfection in Latin America. PLoS Negl Trop Dis 2014 8: e 3136.
20. Marty P (2005) Les leishmanioses viscérales. Épidémiologie et Diagnostic. 6èmes Journées Nationales d’Infectiologie Nice. Lettre des orateurs de sessions de communications orales thématiques. Médecine et Maladies 35: S72-S73.
21. Montagnier L (1998) SIDA et infection par le VIH. Flammarion, Paris, p: 63.
22. Montaltan C, Calleja JL, Erice A, Laguna F, Clotet B, et al. (1990) Visceral leishmaniasis in patients infected with human immunodeficiency virus. Co-operative group for the study of leishmaniasis in AIDS. J Infec 21: 261-270.
23. Montana M, Choochi N, Monges P, Ravaux I, Faraud F, et al. (2004) Liposomal amphotericin B in secondary prophylaxis of visceral leishmaniasis in HIV-infected patients: Report of five clinical cases. Pathol Biol (Paris) 52: 66-75.
24. Okome-Nkoumou M, Bogoukouma JB, Kombila M (2006) Les maladies opportunistes de l’infection par le VIH à l’hôpital Fondation-Jeanne-Enbori de Libreville, Gabon. Med Trop 66: 167-171.
25. ONUSIDA (2015) estimations de 2015 données en ligne AIDS info.
26. WHO (2010) Control of the Leishmaniasis. Geneva, WHO.
27. Oumar AA, Dao S, Diarlo S, et al. (2008) Prévalence des infections opportunistes au cours du sida en milieu hospitalier de Bamako, Mali. Louvain Med 1: 12-17.
28. Pagliano P, Rossi M, Rescigno C, Allieti S, Coppola MG, et al. (2003) Mediterranean visceral leishmaniasis in HIV adults: A retrospective analysis of 64 consecutive cases (1995-2001). J Antimicrob Chemother 52: 264-268.
29. Pintado V, Martin-Rabadán P, Rivera ML, Moreno S, Bouza E (2001) Visceral leishmaniasis in human immunodeficiency (HIV)-infected and non-HIV-infected patients. A comparative study. Medicine (Baltimore) 80: 54-73.
30. Pizzuto M, Piazza M, Senese D, Scalampoga C, Calattini S, et al. (2001) Role of PCR in diagnosis and prognosis of visceral leishmaniasis in patients coinfected with human immunodeficiency virus type 1. J Clin Microbiol 39: 357-361.
31. UNAIDS (2013) World AIDS day report.
32. Desjeux P, Aljar V (2003) Leishmaniose/HIV co-infections: Epidemiology in Europe. Ann Transp Med Parasitol 97 Suppl 1: 3-15.
33. Rosenthal E, Marty P, DelGiudice P, Pradier C, Ceppi C, et al. (2000) HIV and leishmaniasis coinfection: A review of 91 cases with focus on typical locations of Leishmania. Clin Infect Dis 31: 1093-1095.
34. Russo R, Lagana F, LopezVez R, Medrano FJ, Rosenthal E, et al. (2003) Visceral leishmaniasis in those infected with HIV: clinical aspects and other opportunistic infections. Annals of Tropical Medicine & Parasiology 97: S99-S105.
35. World Health Organization (1998) Epidemiological analysis of 692 retrospective cases of leishmaniasis/HIV co-infection.
36. Aljar V, Apaprico P, Aseffa A, Den Boer M, Cañavate C, et al. (2008) The relationship between leishmaniasis and AIDS: The second 10 years. Clin Microbiol Rev 21: 334-359.
37. Cazenin F., et al. (2013) Découvrents de séropositivité VIH et sida – France, 2003-2011. Bull Epidémiologique Hebd 333: 40.
38. Berhe N, Wolday D, Hallu A, Abraham Y, Ali A, et al. (1999) HIV viral load and response to antileishmanial chemotherapy in co-infected patients. AIDS 13: 1921-1925.
39. Cabiè A, Mathonier S, Leprêtre A, Bouchaud O, Deluol AM, et al. (1992) Visceral leishmaniasis in HIV infection: A totally opportunistic infection. Presse Med 21: 1658-1662.
40. de la Loma A, Alvar J, Martinez Galiano E, Blázquez J, Alcalá Muñoz A, et al. (1985) Leishmanioses or AIDS? Trans R Soc Trop Med Hyg 79: 421-422.
41. Desjeux P, Aljar V, Gradoni I, Gramiccia M, Mediano F, et al. (1996) Epidemiological analysis of 692 retrospective cases of leishmaniasis HIV coinfection. WHO, Leish, pp: 96-103.
42. Rosenthal E, Marty P, Le Fichoux Y, Cassuto JP (2000) Clinical manifestations of visceral leishmaniasis associated with HIV infection: A retrospective study of 91 French cases. Ann Trans Med Parasitol 94: 37-42.
43. Srivastava P, Dayama A, Mehrotra S, Sundar S (2011) Diagnosis of visceral leishmaniasis. Trans R Soc Trop Med Hyg 105: 1-6.
44. Davidson RN (1998) Practical guide for the treatment of leishmaniasis. Drugs 56: 1009-1018.

45. Alvar J, Cañavate C, Gutiérrez-Solar B, Jiménez M, Laguna F, et al. (1997) Leishmania and human immunodeficiency virus co-infection: The first 10 years. Clin Microbiol Rev 10: 298-319.

46. Sundar S (2001) Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 6: 849-854.

47. Prajapati VK, Mehrotra S, Gautam S, Rai M, Sundar S (2012) In vitro antileishmanial drug susceptibility of clinical isolates from patients with Indian visceral leishmaniasis - status of newly introduced drugs. Am J Trop Med Hyg 87: 655-657.